Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Join SI Premium – FREE
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.80), $0.42 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $157 million versus the consensus estimate of $130.76 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2025 EPS of $875.00-$900.00, versus the consensus of $866.50.
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Starbucks (SBUX) isn't buying Chipotle Mexican Grill (CMG) - CNBC
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
- UBS Reiterates Buy Rating on Chipotle Mexican Grill (CMG), Sees Likelihood of Starbucks Transaction as 'Somewhat Low'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
